[caption id="attachment_70470" align="alignleft" width="150"] Dr. Dobbins, PharmD[/caption] MedicalResearch.com Interview with: Duncan Dobbins, PharmD, MHI Geisinger College of Health Sciences Scranton, Pennsylvania MedicalResearch.com: What prompted this commentary, and what did you find? Response: In theory, there could be a drug interaction between immunotherapy and medical cannabis. A small (N=102) observational report from Israel appeared to find that immunotherapies worked much less well in cancer patients who also used medical cannabis.¹ However, a follow up report² took about two weeks and involved manually rechecking the math and data-analysis. Several discrepancies emerged between the methods and results. Two-tailed tests were listed in the methods yet one-tailed p values appeared in the results. Arithmetic errors, some traceable to unconventional “floor” rounding, affected key percentages. Multiple p values in Table 1 (21 out of 22) could not be reproduced with the stated tests. Finally, smoking status, a key confound, was not reported. Taken together, these issues complicate interpretation and highlight how small computational slips can cascade into larger inferential uncertainty. For this follow-up report, I was asked, “Do you think AI could have double checked this math?”